TCIM
CORT icon

TIAA CREF Investment Management’s Corcept Therapeutics CORT Stock Holding History

TIAA CREF Investment Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$3.78M Buy
321,615
+74,751
+30% +$929K ﹤0.01% 1620
2018
Q4 		$3.3M Sell
246,864
-92,894
-27% -$1.23M ﹤0.01% 1637
2018
Q3 		$4.76M Sell
339,758
-16,489
-5% -$230K ﹤0.01% 1599
2018
Q2 		$5.6M Sell
356,247
-6,683
-2% -$116K ﹤0.01% 1521
2018
Q1 		$5.97M Sell
362,930
-112,928
-24% -$2.09M ﹤0.01% 1445
2017
Q4 		$8.59M Sell
475,858
-71,752
-13% -$1.3M 0.01% 1226
2017
Q3 		$10.6M Buy
547,610
+200,439
+58% +$2.99M 0.01% 1116
2017
Q2 		$4.1M Buy
347,171
+2,360
+0.7% +$25.7K ﹤0.01% 1725
2017
Q1 		$3.78M Buy
344,811
+27,071
+9% +$238K ﹤0.01% 1766
2016
Q4 		$2.31M Buy
317,740
+23,638
+8% +$185K ﹤0.01% 2110
2016
Q3 		$1.91M Buy
294,102
+11,270
+4% +$65.5K ﹤0.01% 2201
2016
Q2 		$1.54M Buy
282,832
+83,379
+42% +$434K ﹤0.01% 2276
2016
Q1 		$933K Sell
199,453
-29,360
-13% -$114K ﹤0.01% 2510
2015
Q4 		$1.14M Buy
228,813
+18,019
+9% +$81.3K ﹤0.01% 2503
2015
Q3 		$793K Hold
210,794
– – ﹤0.01% 2709
2015
Q2 		$1.27M Sell
210,794
-6,627
-3% -$40.6K ﹤0.01% 2575
2015
Q1 		$1.22M Hold
217,421
– – ﹤0.01% 2505
2014
Q4 		$652K Buy
217,421
+2,488
+1% +$7.58K ﹤0.01% 2871
2014
Q3 		$576K Sell
214,933
-6,307
-3% -$16.7K ﹤0.01% 2914
2014
Q2 		$619K Buy
221,240
+17,582
+9% +$51.9K ﹤0.01% 2955
2014
Q1 		$888K Buy
203,658
+15,970
+9% +$55.8K ﹤0.01% 2703
2013
Q4 		$604K Hold
187,688
– – ﹤0.01% 2907
2013
Q3 		$298K Buy
187,688
+9,531
+5% +$16.8K ﹤0.01% 3025
2013
Q2 		$308K Buy
+178,157
New +$320K ﹤0.01% 3023

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

TIAA CREF Investment Management's CORT Position: Q1 2019 in Review

TIAA CREF Investment Management increased its Corcept Therapeutics (CORT) stake by 30% in Q1 2019, buying an estimated $929K and bringing the position to 321,615 shares worth $3.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1620.

TIAA CREF Investment Management first reported a position in CORT in Q2 2013 and has held it in 24 quarters since. The position peaked at $10.6M in Q3 2017. 208 funds tracked by Wall St. Rank hold CORT as of Q1 2019.

  • TIAA CREF Investment Management held 321,615 shares of Corcept Therapeutics worth $3.78M as of Q1 2019.
  • TIAA CREF Investment Management bought 74,751 Corcept Therapeutics shares in Q1 2019, an estimated $929K.
  • Corcept Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1620 holding.
  • TIAA CREF Investment Management first reported a position in Corcept Therapeutics in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Corcept Therapeutics position peaked at $10.6M in Q3 2017.
  • 208 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.